Meet TaiRx

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need.

With Taiwan as our home base, we have successfully recruited many experts and consultants in new drug development worldwide. With our extensive experience and expertise in drug development, we can rapidly add value to our product line by moving the progress of our drug products forward. We are committed to our pursuit of high quality and scientific excellence, and establishing global collaboration and partnering. Our goal is to become a global drug development company and deliver new therapeutic hopes for the severe diseases.

Vision

TaiRx, Inc. is a R&D based pharmaceutical company with global talents focusing on the new drug development for Asian and global markets. Our team has profound global drug development knowledge and experience to expedite the drug development process. We strive to protect people’s health and uproot the threat of diseases.

We dedicate ourselves to:

Continuously achieve the milestones of our drug development to prove their safety and efficacy; expand global patent coverage to protect our intellectual property and increase the product market value.

Establish sales and marketing partners in Asia-pacific region, and build strong sales network with our partners

Collaborate with global pharma companies for late stage product development, and expand global licensing opportunity.

Recruit talents in new drug development and strengthen integrated team with global standard.

Continue to evaluate and in-license new drug candidates with high market potential to ensure a sustainable product pipeline for the long-term business success.

Innovation

At TaiRx, we strive to become an international brand. With our profound experience and expertise in new drug development, we are fully capable of evaluating the drug efficacy, patent coverage, market potential, and regulatory feasibility for our selected drug candidates. Through integrated process of pre-clinical, clinical, and regulatory science, we effectively manage our program to achieve key milestones of new drug development.

Management Team

Andrew Lin

Chairman

Mr. Lin received his MBA from The University of Chicago. He also graduated with an M.S. in electrical and computer engineering from the University of Massachusetts at Amherst. Mr. Lin was elected as the Chairman of TaiRx, Inc. on December 9, 2020. He strives to lead the company in achieving the most stretching strategic goals and providing optimal financial rewards to the shareholders. Before joining TaiRx, Mr. Lin was the Chairman of Lotus Pharmaceutical, the largest pharma company in Taiwan. He was also the CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy. Prior to his biotech career, Mr. Lin possessed various senior executive positions such as General Manager of JPMorgan Securities, CFO of LITE-ON Group and Managing Director of Greater China for Macquarie Capital. He also worked for AT&T Bell Labs and McKinsey & Company in R&D and management consulting fields. Mr. Lin has a wealth of experience in strategic management, R&D and capital markets.

Du-Shieng Chien, Ph.D.

President and CEO

Dr. Chien, the co-founder of TaiRx, Inc., received his Ph.D. in Biopharmaceutics and Pharmacokinetics from the University of Iowa in 1986. He has more than 30 years of knowledge and management experience in new drug research and development during his tenure with Allergan, Bayer, and Neurogen.

In 2002, Dr. Chien returned to Taiwan and joined the National Health Research Institutes as the Associate Director of the Division of Biotechnology and Pharmaceutical Research. He later served as the President and CEO of SunTen Phytotech. In 2010, he established Efficient Pharma Management Corp. to provide services in technical and regulatory consultation and project management for biotech industry.

Yi-Wen Chu, Ph.D.

Senior Vice President

Dr. Chu, the co-founder of TaiRx, Inc., received her Ph.D. in Cancer Biology from University of Arizona. Her scientific specialty is molecular and cellular mechanism of cancer metastasis. She has more than 20 years of experience in research and management of scientific affairs. Dr. Chu served as the Chief of Planning and Evaluation Office, and Associate Director of Intramural Research Affairs at the National Health Research Institutes. She later joined SunTen Phytotech as Vice President, responsible for the management of new drug development programs and business development prior to establish the Efficient Pharma Management Corp. with Dr. Chien in 2010 and served as the President and CEO of the company. She now serves as the Senior Vice President in TaiRx, managing the company operation and strategic development.

Jackson Huang, M.A.

Chief Financial Officer

Mr. Jackson Huang is the Chief Financial Officer of TaiRx. Jackson earned his Master degree in Accountancy from University of Missouri in 1997. Jackson has since accumulated his extensive knowledge and experience in banking, accounting, and internal controls affairs while working at Shanghai Commercial & Saving Bank and KPMG CPA Firm. He served as the CFO at Golden Biotechnology Corp. prior to joining TaiRx. He has worked in various industries and has extensive knowledge regarding the regulations of Taiwan Stock Exchange, tax administration affairs, and public company compliance.

Scientific Advisory Committee

Toxicology and Safety Management

Harry M. Olson, DVM, Ph.D.

Vice President, Worldwide Safety Sciences, Pfizer; Director, Department of Drug Safety Evaluation, Bayer Corp.; Senior Director, Department of Toxicology, Sanofi Winthrop Inc.

Cancer Biology

Mary J.C. Hendrix, Ph.D.

President of Shephard University. Mary also serves in the National Cancer Institute (NCI) Board of Scientific Advisors. She was the former President and Chief Scientific Officer of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and the former Deputy and Associate Director of Basic Research at Holden Comprehensive Cancer Center, University of Iowa.

Cancer Biology and Clinical Research

Jang-Yang Chang, M.D.

President of Taipei Cancer Center. Former Director of Institute of Biotechnology and Pharmaceutical Research (IBPR) at NHRI. And Former Vice President of National Cheng Kung University.